Key result
Downregulated miR-342-3p is linked to poor chronic heart failure prognosis and suppresses cardiac fibrosis.
Why the study?
Myocardial fibrosis is the core pathological feature of chronic heart failure (CHF), yet effective therapeutic targets for this process remain limited.
Does miR-342-3p regulate myocardial fibrosis by targeting CRIM1 and serve as a diagnostic and prognostic marker in patients with chronic heart failure?
Case-Control (n=158)
Does miR-342-3p regulate myocardial fibrosis by targeting CRIM1 and serve as a diagnostic and prognostic marker in patients with chronic heart failure?
miR-342-3p is downregulated in chronic heart failure patients and inhibits cardiac fibrosis by directly targeting CRIM1, identifying it as a potential diagnostic biomarker and therapeutic target for myocardial fibrosis in CHF.
Answers are grounded in this paper and cite their sources.
miR-342-3p/CRIM1 patterns warrant validation as HF biomarkers; hypothesis-generating and should not yet change practice.
Chronic heart failure (CHF) is characterized by myocardial fibrosis as its core pathological feature, yet effective therapeutic targets for this process remain limited. A total of 85 CHF patients and 73 healthy controls were included to measure the expression of miR-342-3p and CRIM1 in peripheral blood and to evaluate their clinical relevance. In in vitro experiments, miR-342-3p mimics and CRIM1 overexpression were used to functionally assess TGF-β1-induced fibrosis in human cardiac fibroblasts. Comprehensive experiments, including qPCR, CCK-8, Transwell, and dual-luciferase reporter assays, demonstrated that miR-342-3p regulates fibroblast proliferation, migration, and the expression of fibrosis-related genes by targeting CRIM1. Clinical analysis indicates that peripheral blood miR-342-3p expression in CHF patients is significantly lower than in healthy controls, while CRIM1 expression is significantly higher. Both are associated with clinical indicators such as heart function classification, BNP, LVEF, and LAVI. miR-342-3p showed potential diagnostic value for CHF, and its low expression was associated with an unfavorable prognosis. In vitro experiments found that TGF-β1 inhibits miR-342-3p expression, while overexpression of this miRNA promotes cell proliferation and migration and reduces the levels of fibrosis markers. Mechanistically, CRIM1 has been confirmed as a direct target of miR-342-3p, mediating its anti-fibrotic effect. miR-342-3p is downregulated in CHF and inhibits cardiac fibrosis by targeting CRIM1, suggesting that it may serve as a novel diagnostic marker and potential therapeutic target for CHF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a case-control in Chronic heart failure (CHF) (n=158). miR-342-3p and CRIM1 expression vs. Healthy controls was evaluated on Peripheral blood expression of miR-342-3p and CRIM1, clinical relevance, and inhibition of TGF-β1-induced cardiac fibrosis. Peripheral blood miR-342-3p was downregulated in 85 chronic heart failure patients vs 73 controls, was associated with poor prognosis, and inhibited cardiac fibrosis in vitro by targeting CRIM1.
Synapse has enriched 10 related papers. Consider them for comparative context: